Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
April 19, 2016
Assignee:
AbbVie Biotherapeutics Inc.
Inventors:
Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
Abstract: The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.
Type:
Grant
Filed:
February 17, 2011
Date of Patent:
April 12, 2016
Assignee:
Mesoblast International Sàrl
Inventors:
Vincent Frans Maria Segers, Anthony Sandrasagra, Yan Qiu
Abstract: Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The complexes and compositions can be used for administration to subjects, such as for treating a subject with a musculoskeletal disease such as osteoarthritis and/or degenerative joint disease. The complexes and compositions can be used in different mammals, including dogs, horses, and humans.
Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
Type:
Grant
Filed:
January 2, 2014
Date of Patent:
March 22, 2016
Assignee:
GLENMARK PHARMACEUTICALS S.A.
Inventors:
Antoine Attinger, Jonathan Albert Back, Stanislas Blein, Rami Lissilaa, Darko Skegro
Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.
Type:
Grant
Filed:
July 23, 2014
Date of Patent:
February 2, 2016
Assignee:
Janssen Biotech, Inc.
Inventors:
Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasy
Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
Abstract: Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.
Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Type:
Grant
Filed:
October 3, 2013
Date of Patent:
January 12, 2016
Assignee:
Baylor Research Institute
Inventors:
Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
Abstract: A nutritional composition comprising a partially hydrolyzed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-? per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed.
Type:
Grant
Filed:
February 22, 2013
Date of Patent:
January 5, 2016
Assignee:
Nestec S.A.
Inventors:
Annick Mercenier, Marie-Claire Fichot, Adrian Zuercher
Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.
Type:
Grant
Filed:
March 21, 2013
Date of Patent:
January 5, 2016
Assignee:
HEPACORE LTD.
Inventors:
Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali
Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
Type:
Grant
Filed:
April 6, 2011
Date of Patent:
January 5, 2016
Assignee:
AbbVie Inc.
Inventors:
Lorenzo Benatuil, Tariq Ghayur, Carrie L. Goodreau, Peter C. Isakson, Jochen Salfeld
Abstract: The present invention relates to novel therapies that utilize HSP70 fusion proteins for the treatment of disorders or conditions regulated by HSP70.
Type:
Grant
Filed:
December 15, 2012
Date of Patent:
December 22, 2015
Inventors:
Sergei B Onikienko, Alex Nivorozhkin, Alexander V Zemlyanoi, Mikhail Viktorovich Shorokhov, Vladimir Ivanovich Pereguda, Valery Aleksandrovich Chereshnev
Abstract: Injections for treating and preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, diseases classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or diseases classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix.
Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (?) and IL-21. The composition containing the double antagonist to TNF-? and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.
Type:
Grant
Filed:
March 18, 2011
Date of Patent:
December 1, 2015
Assignees:
Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, the Catholic University of Korea
Inventors:
Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Sun-Ha Yoon, Ji Hyun Park, Eun Jung Song, Jong-Ho Lee, Min Ji Seo, Sun Jung Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
Abstract: The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases.
Type:
Grant
Filed:
May 27, 2010
Date of Patent:
October 13, 2015
Assignee:
The United States Government as Represented by the Department of Veterans Affairs
Abstract: An excellent protein stabilizer is provided, which has the following effects: (1) low probability with contamination of pathogens, (2) the effect of stabilization on photoproteins, and (3) minimization of loss of activity under lyophilizing conditions. A peptide from fish is used as the active ingredient for the protein stabilizer.